资讯

The Pharma Letter46 分钟
Biopharma innovation meets market headwinds tempering optimism
The biopharmaceutical industry is grappling with a complex mid-year outlook in 2025, as accelerating innovation collides with ...
The Pharma Letter53 分钟
Scholar Rock data show promise for muscle-preserving combo with Zepbound
Scholar Rock (Nasdaq: SRRK) has unveiled encouraging Phase II data for its experimental therapy apitegromab, showing the drug ...
The Pharma Letter1 小时
Rare epilepsy specialist Actio secures $66 million in series B
US biotech Actio Biosciences has raised $66 million in a series B round to support its pipeline of genetically targeted ...